More about Granules India Limited
Fundamentals for Granules India Limited
Regulatory Filings for Granules India Limited
IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for Granules India Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. Granules India Limited was founded in 1984 and is based in Hyderabad, India.
Revenue projections:
Granules India Limited is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 19.964533 |
| debtToEquity | 45.369000 |
| earningsGrowth | 0.276000 |
| revenueGrowth | 0.220000 |
| grossMargins | 0.618960 |
| operatingMargins | 0.169010 |
| trailingEps | 22.460000 |
| forwardEps | 30.005710 |
GRANULES's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
GRANULES's positive earnings and revenue growth point to business expansion on the horizon. The company is positioned for continued success, with increasing profits and revenue growth highlighting a strong path forward for future growth.
GRANULES's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that GRANULES's financial performance will improve in the current financial year.
Price projections:
GRANULES's price projections have gradually risen, indicating growing confidence in the company's prospects. This upward trend suggests that analysts expect GRANULES to continue performing well in the future.
Recommendation changes over time:
GRANULES has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view GRANULES as a stable option to park their money and potentially benefit from the company's continued growth and profitability.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape